- Home
- Automated
- List of product information
- CLARITYN-D 24HOUR EXTENDED RELEASE TABLET [SIN12246P]
CLARITYN-D 24HOUR EXTENDED RELEASE TABLET [SIN12246P]
Active ingredients: CLARITYN-D 24HOUR EXTENDED RELEASE TABLET
Product Info
CLARITYN-D 24HOUR EXTENDED RELEASE TABLET
[SIN12246P]
Product information
Active Ingredient and Strength | LORATADINE - 10 MG |
Dosage Form | TABLET, SUGAR COATED |
Manufacturer and Country | SAG MANUFACTURING S.L.U. - SPAIN |
Registration Number | SIN12246P |
Licence Holder | BAYER (SOUTH EAST ASIA) PTE LTD |
Forensic Classification | PHARMACY ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | R01BA52 |
Indications and usage
Clarityn-D® 24 Hour Extended Release is indicated for the relief of symptoms associated with allergic rhinitis and the common cold, including nasal congestion, sneezing, rhinorrhea, pruritus and lacrimation.
Clarityn-D® 24 Hour Extended Release is recommended when both the antihistaminic properties of loratadine and the decongestant effect of pseudoephedrine sulfate are desired.
Dosage and Administration
Adults and Children 12 years of age and over: One Clarityn-D® 24 Hour Extended Release Tablet once daily. Clarityn-D® 24 Hour Extended Release may be taken without regard to meal time.
Patients who have a history of difficulty in swallowing tablets or who have known upper gastrointestinal narrowing or abnormal esophageal peristalsis should not use this product (see Precautions and Adverse Reactions – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Contraindications
Clarityn-D® 24 Hour Extended Release Tablets are contraindicated in those who have shown sensitivity or idiosyncrasy to their components or to adrenergic agents. Clarityn-D® 24 Hour Extended Release Tablets also are contraindicated in patients receiving MAO inhibitor therapy or within two weeks of discontinuing such treatment and in patients with narrow angle glaucoma, urinary retention, severe hypertension, severe coronary artery disease and hyperthyroidism.
